B38
/ Luhe Hospital, Chinese Academy of Sciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 03, 2022
An engineered bispecific human monoclonal antibody against SARS-CoV-2.
(PubMed, Nat Immunol)
- "A noncompeting pair of human neutralizing antibodies (B38 and H4) blocking SARS-CoV-2 binding to its receptor, ACE2, have been described previously...Furthermore, prophylactic and therapeutic application of bsAb15 reduced the viral titer in infected nonhuman primates and human ACE2 transgenic mice. Therefore, this bsAb is a feasible and effective strategy to treat and prevent severe COVID-19."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1